While our study was not powered for formal reclassification or net-benefit testing, these prospective analyses are planned and will clarify where Cav-3 is most effective (e.g., in populations where peptide interpretation is confounded by obesity, CKD, or AF). The gene discussed is CAV3; the disease is Obesity.